Deutsche Bank AG Buys 504,336 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Deutsche Bank AG raised its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 47.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,567,535 shares of the biotechnology company's stock after acquiring an additional 504,336 shares during the quarter. Deutsche Bank AG owned approximately 0.98% of Ironwood Pharmaceuticals worth $6,944,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Journey Strategic Wealth LLC purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $45,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $47,000. Envestnet Asset Management Inc. purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $50,000. Xponance Inc. purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $50,000. Finally, SG Americas Securities LLC purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $53,000.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IRWD. Jefferies Financial Group restated a "hold" rating and set a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $1.00 price target (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Craig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Citizens Jmp lowered Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Monday, April 14th. Finally, Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $4.78.

Ironwood Pharmaceuticals Stock Down 8.7%

IRWD traded down $0.05 on Friday, hitting $0.57. The company had a trading volume of 5,063,577 shares, compared to its average volume of 2,576,288. The company has a market cap of $91.64 million, a PE ratio of -18.88 and a beta of 0.37. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.53 and a 12-month high of $7.11. The business's fifty day simple moving average is $0.98 and its 200 day simple moving average is $2.43.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $41.14 million for the quarter, compared to analysts' expectations of $67.02 million. On average, analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.